An Evaluation of Medication Adherence to Tyrosine Kinase Inhibitors Among Chronic Myeloid Leukemia Patients Underwent Medication Therapy Adherence Clinic in a Malaysian Tertiary Hospital
Abstract
Introduction: The treatment of chronic phase chronic myeloid leukemia (CML) has changed dramatically within the last two decades with the emergence of tyrosine kinase inhibitors (TKI). Treatment adherence to long-term TKI is pivotal to improving clinical outcomes in CML patients. Objective: To evaluate medication adherence to TKI and contributory variables affecting medication adherence among CML patients underwent Medication Therapy Adherence Clinic (MTAC). Method: This was a single-centre cross-sectional study conducted between January and December 2021. Malaysia Medication Adherence Assessment Tool (MyMAAT) was employed to assess medication adherence among CML MTAC patients. Descriptive statistics were used to summarise adherence information. Fisher’s exact test was performed to examine relationships between TKI adherence level, demographic and clinical variables. Result: Records of 41 patients (61% male, 39% female) at average age of 51 years old (range = 26 to 75) were analysed. They had been taking imatinib (48.8%) and nilotinib (51.2%) for an average of 6.3 years (range = 17 days to 18 years). Overall, 90% of the patients were adherent (MyMAAT score ≥ 54) to their TKI treatment (95% of patients on imatinib, 86% of patients on nilotinib). Medication adherence to TKI was not significantly influenced by demographic variables (i.e. age, gender) and clinical variables (i.e. years on TKI, number of TKI pills per day, type of TKI therapy). Conclusion: Majority of the CML MTAC patients (90%) were adherent to their TKI therapy. Adherence scores were not affected by the demographics and clinical variables investigated in this study. This affirms the role of pharmacists in implementing an individualised and comprehensive intervention strategy.